Florfenicol, a synthetic drug with chemical structure and spectrum of antibacterial activity similar to chloramphenicol, has been shown to be effective against a number of bacterial pathogens. However, there are increasing signs of florfenicol-resistant bacteria due to the misuse and overuse of florfenicol in aquaculture. In the present study, florfenicol had a higher bactericidal efficacy in the presence of myo-inositol, which may be due to the ability of myo-inositol to increase susceptibility of Aeromonas hydrophila to florfenicol. Furthermore, in two different infected models, co-administration of myo-inositol and florfenicol significantly reduced the bacterial load in the liver, kidney and spleen tissues of A. hydrophila-infected Cyprinus carpio, and greatly increased the survival rate of infected fish. Finally, it was also found that myo-inositol exhibited synergistic action with other antibiotic drugs including neomycin sulfate, ceftriaxone and enrofloxacin. The results obtained in this study suggest that myo-inositol as an efficient adjuvant to antibiotic drugs could be useful in increasing the antimicrobial activity of antibiotic drugs against A. hydrophila infection, and could also be useful to help decrease the occurrence of antibiotic overuse in aquaculture.
INTRODUCTION
Today, aquaculture is the fastest growing food-producing sector in the world, with an average annual growth rate of 8. 9% since 1970 (Bondad-Reantaso et al. 2005 . However, aquaculture production is vulnerable to adverse impacts of disease and environmental conditions. Different opportunistic bacterial pathogens cause devastating losses to the fish industry in terms of high morbidity and mortality, impeding both economic and social development, diminishing growth and increasing expenditure on chemicals as preventive and treatment measures (Lafferty et al. 2015) . Of these pathogens, Aeromonas hydrophila is the most common zoonotic bacteria in aquaculture.
Aeromonas hydrophila are Gram-negative bacteria that are widely distributed in aquatic environments (Janda and Abbott 2010) and are an opportunistic pathogen for fish, reptiles, amphibians and humans; they are capable of causing hemorrhagic septicemia and skin ulceration in aquatic animals and diarrhea in mammals (Nielsen et al. 2001; Peatman et al. 2018) . It is known that A. hydrophila cause motile Aeromonas septicemia in fish such as carp (Cyprinus carpio) (Harikrishnan, Rani and Balasundaram 2003) , channel catfish (Ictalurus punctatus) (Peatman et al. 2018) and tilapia (Oreochromis niloticus) (Pachanawan, Phumkhachorn and Rattanachaikunsopon 2008) , leading to huge economic losses in farmed and feral fishes.
Antibiotics are considered to be the most important and indispensable strategies in animals for prevention and treatment of bacterial infections, and also as growth promoters (Cabello et al. 2013) . However, the inappropriate overuse of antibiotic drugs in the aquaculture industry has led to the development of antibiotic resistance, thereby reducing antibiotic efficacy (Hatha et al. 2005; Stratev and Odeyemi 2016) . Moreover, the accumulation of antibiotics in animals and water ponds can be potentially risky to human health and the water environment (Liu, Steele and Meng 2017) . Given the limitations of antibiotic usage described above, it is of particular interest to develop novel approaches that prevent or revert the antibiotic resistance. Fortunately, some non-antibiotic compounds with little or no antibiotic activity have been found to act as antibiotic adjuvants, which could enhance the antibiotic activity of old antibiotics (Wright 2016) .
In this study, it was found that myo-inositol enhanced antibiotic activity of florfenicol in in vitro and in vivo assays. The coadministration of florfenicol and myo-inositol improved the bactericidal efficacy of the treatment of A. hydrophila infection and greatly increased the survival rate of infected fish. Therefore, myo-inositol can be used as a new antibiotic adjuvant, which reduces antibiotic usage and facilitates the prevention and treatment of bacterial infections in aquatic animals.
MATERIALS AND METHODS

Fish and bacterial strain
Common carp (C. carpio) (body weight: 20 ± 3 g) were provided by the Animal Breeding Station of Henan Normal University and used in the experiments. During the experiment the water was continuously aerated, pH 8.0 ± 0.2, dissolved oxygen 7 ± 0.5 mg/L, water hardness 20 ± 1 mg/L CaCO 3 , total ammonia 0.006 ± 0.001 mg/L and nitrite 0.03 ± 0.01 mg/L. Temperature was maintained at 25 ± 2
• C. Fish were fed twice daily for a week before experiments. Aeromonas hydrophila used in the experiments were isolated and stored in our laboratory. The bacteria were grown in Brain Heart Infusion (BHI) broth at 28
• C for 24 h. The cells were harvested by centrifugation (8000 r.p.m., 5 min), washed and resuspended with 0.85% saline. The optical density at 600 nm (OD 600 ) was adjusted to 0.6 for the follow-up test. The lethal dose 50 (LD 50 ) was determined by intraperitoneal infection into carp at 25
• C, and calculated according to Reed and Muench (Thakur and Fezio 1981) . The LD 50 concentration of A. hydrophila in carp was 5 × 10 6 colony-forming units (CFU)/fish. Carp started to
show infectious symptoms after 12 h and died from 24 h; no further death occurred after 48 h.
Determination of minimum inhibitory concentration (MIC)
The minimal inhibitory concentration (MIC) of florfenicol against A. hydrophila was investigated according to the USA National Committee for Clinical Laboratory Standards procedure using a 2-fold standard broth micro-dilution method as described previously (Li et al. 2007 
Antibiotic bactericidal assays in vitro
Antibiotic bactericidal assay was carried out as previously described (Allison, Brynildsen and Collins 2011) . Briefly, a single colony of A. hydrophila was grown in 100 mL of BHI broth overnight at 28
• C. An appropriate amount of bacterial culture was centrifuged at 8000 r.p.m. for 5 min, the pellet was washed twice with 0.85% saline and re-suspended in M9 minimal medium containing 10 mM sodium acetate, 1 mM MgSO 4 and 0.1 mM CaCl 2 , diluted to OD 600 of 0.6. Subsequently, myoinositol was added to the bacterial suspension and an appropriate amount of antibiotic drugs in a test tube, to a total volume of 5 mL, with M9 medium and incubated at 28
• C for 6 h.
To determine bacterial counts, a 100 μL sample was collected at certain time points and serially diluted. An aliquot of 10 μL of each dilution was plated on BHI agar plates and incubated at 28
• C overnight. The colonies were counts and CFU/mL was calculated. The number of bacterial colonies in samples that were not treated with antibiotic or myo-inositol was considered as the initial number of bacteria. Only those dilutions yielding 20-200 colonies were eligible for statistical analysis. The survival rate of bacteria (% survival) was defined as the percentage of bacterial CFU of the antibiotic-and/or metabolite-treated samples compared with the initial bacterial CFU.
Bacterial eradication assay in vivo
Healthy fish were intraperitoneally injected with 0.1 mL bacterial suspension of A. hydrophila (5 × 10 6 CFU/mL) into the carp, which is a safe dose for fish, and no obvious signs of disease were observed. After 24 h post-infection, all fish were randomly divided into four groups (n = 6). The fish in the control group, myo-inositol group, florfenicol group and myo-inositol plus florfenicol group were injected with 0.1 mL solutions as follows: 0.85% saline, 50 mg/kg myo-inositol, 25 mg/kg florfenicol, and co-administration of 50 mg/kg myo-inositol and 25 mg/kg florfenicol, respectively. After 24 h of treatment, the liver, kidney and spleen tissues were excised, weighed and homogenized in 1 mL of saline. The homogenates were then serially diluted to determine the bacterial load (CFU/g) by using the plate count method, as described above.
Bacterial infection and drugs therapy
Each healthy fish was challenged with 0.1 mL 1 × 10 8 CFU/mL A. hydrophila. For drug therapy assay, two kinds of treatment including oral and intraperitoneal administration were undertaken. After 1 h of bacterial infection, fish were randomly divided into four groups for each treatment, 30 fish for each group, including saline, 50 mg/kg myo-inositol, 25 mg/kg florfenicol, and co-administration of 50 mg/kg myo-inositol and 25 mg/kg florfenicol, respectively. All fish received a single treatment administered intraperitoneally or orally with 0.1 mL solutions, as described previously (Chen et al. 2015; Zhao et al. 2015) . After drug therapy, the mortality of the infected fish was observed every 12 h for 3 days. The protective ability of the drug was calculated using the equation: drug protective rate = [1 -(mortality rate of drug administration group/mortality rate of the control group)] × 100%.
Statistical analysis
The data were expressed as means ± standard deviation (SD). Data obtained from bactericidal efficacy, bacterial load and protective rate of the drugs were analyzed and graphed using GraphPad Prism 6 software (GraphPad Software, CA, USA). Statistical significance was determined by one-way ANOVA. Differences were considered to be significant at P < 0.05 and extremely significant at P < 0.01.
RESULTS
Myo-inositol improved the bactericidal efficacy of florfenicol
In order to examine the bactericidal efficacy of florfenicol in the presence of exogenous myo-inositol, the bactericidal assay was performed by co-incubating myo-inositol and florfenicol with Aeromonas hydrophila. The results showed that cell survival decreased by 3.6-, 5.1-, 12.3-, 26.5-, 55.9-and 146.7-fold with increasing doses of florfenicol from 20 to 200 μg/mL plus 20 mM myo-inositol, compared with cells grown in the presence of florfenicol alone (P < 0.01) (Fig. 1A) . It was also observed that the combination of 20 mM myo-inositol and 40 μg/mL florfenicol resulted in a bacterial survival rate similar to that of 160 μg/mL florfenicol alone. However, in the control group, no antibiotic activity was observed after myo-inositol treatment.
Relative to bacteria incubated with 40 μg/mL or 80 μg/mL florfenicol alone, the survival rate of A. hydrophila decreased by 1.6-to 11.8-fold with 0.625-20 mM myo-inositol plus 40 μg/mL florfenicol (P < 0.01) and 1.9-to 22.0-fold with 0.625-20 mM myoinositol plus 80 μg/mL florfenicol (P < 0.01) (Fig. 1B) . In order to investigate the synergistic effect of 20 mM myo-inositol plus 40 μg/mL or 80 μg/mL florfenicol with an increased exposure time, samples were collected every 2 h and diluted for plate counting. The results in Fig. 1C show a time-dependent bactericidal effect, with the largest effect at 10 h, a 12-and 27-fold decreased in the survival rate, respectively. These results indicated that the addition of myo-inositol significantly improved the bactericidal efficacy of florfenicol.
Myo-inositol improved susceptibility of A. hydrophila to florfenicol
To test the effect of myo-inositol on florfenicol susceptibility, different doses of myo-inositol and florfenicol were added to the culture medium for MIC determination. Antimicrobial susceptibility showed that the MIC of florfenicol against A. hydrophila was 5 μg/mL. As shown in Table 1 , the MIC of A. hydrophila to florfenicol decreased from 5 μg/mL to 1.25 μg/mL or even 0.625 μg/mL in the presence of different concentrations of myo-inositol. When myo-inositol and florfenicol were used in combination, the MIC was dramatically decreased, suggested that myo-inositol increase the susceptibility of A. hydrophila to florfenicol.
Myo-inositol improved the ability of florfenicol to eradicate bacteria
Common carp C. carpio injected with A. hydrophila at a safe dose with 0.1 LD 50 (equivalent to 5.0 × 10 5 CFU/fish) did not show any obvious infection symptoms on the first day. After 24 h of bacterial infection, the infected fish were intraperitoneally injected with 50 mg/kg myo-inositol and/or 25 mg/kg florfenicol. The liver, spleen and kidney of the infected fish were retrieved 24 h after treatment for bacterial counting. The results showed that the synergy of myo-inositol and florfenicol significantly reduced the bacterial count in all three tissues (P < 0.01). Compared with the control group, the bacterial loads of combination groups in the fish liver, kidney and spleen were reduced by 23-, 7.5-and 20-fold, respectively (Fig. 2) . However, the treatment with 25 mg/kg florfenicol alone did not result in a significant treatment efficacy (P > 0.05). In contrast, the myoinositol group treated with 50 mg/kg myo-inositol alone also had a significantly reduced bacterial count in liver and spleen (P < 0.01 and P < 0.05, respectively).
Myo-inositol improves the therapy efficacy of florfenicol against A. hydrophila infection in C. carpio
On the basis of the bacterial eradication assay, the protective efficacy of combination myo-inositol with florfenicol against infection by pathogenic bacteria was determined. The fish were injected with or orally administrated myo-inositol and/or florfenicol at 1 h after challenge with 0.1 mL 1.0 × 10 8 CFU/mL bacteria. The results showed that fish with bacterial infection had a consistent mortality rate within 48 h; the infected fish showed external hemorrhages in fins and intestine, which is the typical symptom of A. hydrophila infection. For injection administration assays, the cumulative mortality rate of fish in the control group was 80%, while the treat- ment efficacy of the florfenicol alone did not cause a significant improvement; the 48-h mortality rate was 70%. In contrast, the co-administration of myo-inositol and florfenicol showed a significant protective efficacy against bacterial infection; the cumulative mortality rate was 6.7%. Furthermore, the myo-inositol exhibited a significant protective effect, with a 48-h mortality rate of approximately 30%. Hence, the co-administration resulted in a protective rate of up to 91.6% (Fig. 3A) .
Similarly, the result of oral administration showed that the cumulative mortality rate of fish in the control group was 86.7%, while the treatment efficacy of florfenicol alone was insignificant, with a 48-h mortality rate of 63.3%. In contrast, the myoinositol treatment resulted in a significant protective effect, with a 48-h mortality rate of approximately 43.3%; a significant increase in survival rate was observed following the co-treatment of myo-inositol and florfenicol, in which the cumulative mortality rate was 16.7%. Hence, the oral co-administration resulted in a protective rate of up to 80.7% (Fig. 3B) .
The above results indicate that both the injection and oral co-administration of myo-inositol and florfenicol are capable of exerting a significant protective efficacy on C. carpio against A. hydrophila infection. However, myo-inositol alone also showed a significant protective effect against A. hydrophila infection. Combined with the results of bacteria eradication, it was speculated that myo-inositol was capable of affecting the fish immune function, which contributed to the eradication of bacterial infections.
Myo-inositol potentiates bactericidal effects of other antibiotic drugs
In order to expand the application of myo-inositol with antibiotic drugs in aquaculture, the bactericidal effect of three other drugs including neomycin sulfate, enrofloxacin and ceftriaxone in the presence of exogenous myo-inositol was studied.
As predicted, the survival rate was decreased with increasing dose of antibiotic drugs, when bacteria were grown in the presence of 20 mM myo-inositol. Relative to bacteria incubated with neomycin sulfate alone, the survival rate of A. hydrophila decreased by 1.8-to 243.0-fold with 4-40 μg/mL neomycin sulfate plus 20 mM myo-inositol (P < 0.01) (Fig. 4A) . For ceftriaxone, viabilities of A. hydrophila were reduced by 3.2-to 52.2-fold with increased doses of ceftriaxone plus 20 mM myo-inositol (P < 0.01) as indicated in Fig. 4B . Similar observations were obtained for enrofloxacin; exogenous myo-inositol improved the bactericidal efficacy of 9-18 ng/mL enrofloxacin (Fig. 4C) . These results indicate that myo-inositol may increase the potential of antibiotic drugs to eliminate A. hydrophila and can serve as adjuvant compound.
DISCUSSION
Bacterial infectious diseases represent a serious risk to animals and humans. However, this problem has been much more serious in the last years with the increase in the prevalence of infections caused by antibiotic-resistant bacteria, and is jeopardizing the essential role played by antibiotics in current medical practices (Rossolini et al. 2014) . Therefore, the search for new compounds able to potentiate the antimicrobial activity of old antibiotics against resistant bacteria has become an important area of research (Bolla et al. 2011) .
Recently, the relationship between bacterial metabolites and antibiotic activity has been proposed in several pathogens. Some special small molecule metabolites such as indole, nitric oxide, hydrogen sulfide and gaseous ammonia regulate the bacterial metabolic environment and alter antibiotic susceptibility in Escherichia coli (Gusarov et al. 2009; Lee et al. 2010; Bernier et al. 2011; Shatalin et al. 2011) . Other exogenous addition of metabolites including carbon sources potentiated aminoglycoside to eliminate E. coli and Staphylococcus aureus biofilms and persisters (Allison, Brynildsen and Collins 2011) , and mannitol significantly improved the bactericidal capability of tobramycin against Pseudomonas aeruginosa (Barraud et al. 2013) . Moreover, several studies based on metabolomics were performed to understand metabolic mechanisms of antibioticresistant bacteria and to identify some crucial biomarkers, including glutamate, alanine, glucose and fructose, that improved the bactericidal efficacy of kanamycin against Edwardsiella tarda through modulating the susceptibility of bacteria by activating the TCA cycle Su et al. 2018) . Other compounds, such as silver and silver nanoparticles, have also been used to enhance the action of existing antibiotics against Gram-negative bacteria, thus strengthening the antibacterial effectiveness for fighting bacterial infections (Morones-Ramirez et al. 2013; Gurunathan 2015) . These compounds that significantly influence bacterial susceptibility to antibiotics could be used as antibiotic adjuvants.
Here, the synergistic action of myo-inositol and florfenicol in in vitro and in vivo assays was determined. This work showed that myo-inositol significantly improved the bactericidal capability of florfenicol against A. hydrophila; the survival rate of bacteria decreased with increasing doses of myo-inositol or florfenicol, and also showed time-dependent effects. It was indicated that the mechanism may be due to the ability of myo-inositol to increase susceptibility of A. hydrophila to florfenicol. The results are similar to those reported previously Su et al. 2018) . Additionally, in two infection models, the co-administration of myo-inositol and florfenicol significantly reduced the bacterial load of A. hydrophila in fish and enhanced the survival ability of fish against A. hydrophila infection. It is indicated that the addition of myo-inositol would potentiate antibacterial efficacy in vivo, permitting reduction of excessive use of antibiotic drugs and the occurrence of bacterial resistance.
Myo-inositol is classified as a vitamin-like nutrient, not only as an essential nutrient for the growth of fish (Shiau and Su 2005) , but it also play an important role in preventing oxidative damage and increases antioxidant enzyme activities (Jiang et al. 2015) . Here, in the bacterial eradication and protective efficacy assays, it is interesting to note that myo-inositol alone also enhanced bacterial eradication and therapy efficacy against bacterial infections. Chen et al. also reported that myo-inositol improves the host's ability to eliminate antibiotic-resistant E. coli (Chen et al. 2015) . In other studies, myo-inositol protected the fish by preventing oxidative damages (Jiang et al. 2014 (Jiang et al. , 2015 .
In conclusion, this is the first report of myo-inositol improving the antibacterial effectiveness of antibiotics. These results describe the capability of myo-inositol to enhance antibiotic activity across a wide range of antibiotics, including florfenicol, neomycin sulfate, ceftriaxone and enrofloxacin, inviting a future study of its use as an antibiotic adjuvant that can be orally taken or injected, and used in a wider clinical setting. Therefore, the present study reports a bright prospect for the prevention and treatment of fish diseases, which will be a benefit in healthy aquaculture and the safety of aquatic products.
